US Patent Issued to IGF Oncology on Jan. 20 for "Insulin-like growth factor-chemotherapeutic conjugate for treating myelodysplastic syndrome" (Minnesota Inventors)

ALEXANDRIA, Va., Jan. 20 -- United States Patent no. 12,527,876, issued on Jan. 20, was assigned to IGF Oncology LLC (Pine Springs, Minn.).

"Insulin-like growth factor-chemotherapeutic conjugate for treating myelodysplastic syndrome" was invented by Hugh McTavish (Pine Springs, Minn.) and Arkadiusz Z Dudek (Vadnais Heights, Minn.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutic...